Long-term Survival of Treated Tuberculosis Patients in Comparison to a General Population In South India: A Matched Cohort Study.

Mortality rate Post-treatment Potential years of life lost Standardized mortality ratio Tuberculosis

Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 23 05 2021
revised: 25 07 2021
accepted: 27 07 2021
pubmed: 2 8 2021
medline: 29 9 2021
entrez: 1 8 2021
Statut: ppublish

Résumé

This study aimed to measure the mortality rate, potential years of life lost, and excess general mortality among individuals treated for pulmonary tuberculosis (TB) in a TB endemic country. A retrospective analysis was conducted on a population-based cohort study of 4022 TB patients and 12,243 gender-matched and age-matched controls from prevalence surveys conducted between 2000 and 2004 in the Thiruvallur district of Tamil Nadu, South India. The mortality rate among TB patients was 59/1000 person-years. The excess standardized mortality ratio was 2.3 (95% CI: 1.7-3.1). The rate of potential years of life lost was 6.15/1000 (95% CI: 5.97-6.33) in the TB cohort compared to the general population of 1.52/1000 (95% CI: 1.46-1.60). Individuals aged >50 years, those underweight (<40 kg), with treatment failures, or lost to follow-up had higher mortality rates when compared with the rest of the TB cohort. The risk of death was significantly higher in the TB cohort until the end of the fourth year when compared with later years. Mortality in the TB cohort was 2.3 times higher than in the age-matched general population. Most deaths occurred in the first year after completing treatment. Post-treatment follow-ups and interventions for reducing comorbid conditions are necessary to prevent deaths.

Identifiants

pubmed: 34333118
pii: S1201-9712(21)00622-6
doi: 10.1016/j.ijid.2021.07.067
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

385-393

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Sriram Selvaraju (S)

ICMR-National Institute for Research in Tuberculosis, Chetput, Chennai, India.

Kannan Thiruvengadam (K)

ICMR-National Institute for Research in Tuberculosis, Chetput, Chennai, India.

Basilea Watson (B)

ICMR-National Institute for Research in Tuberculosis, Chetput, Chennai, India.

Nataraj Thirumalai (N)

ICMR-National Institute for Research in Tuberculosis, Chetput, Chennai, India.

Muniyandi Malaisamy (M)

ICMR-National Institute for Research in Tuberculosis, Chetput, Chennai, India.

Chandrasekaran Vedachalam (C)

ICMR-National Institute for Research in Tuberculosis, Chetput, Chennai, India.

Soumya Swaminathan (S)

ICMR-National Institute for Research in Tuberculosis, Chetput, Chennai, India; Chief Scientist, World Health Organization, Geneva, Switzerland.

Chandrasekaran Padmapriyadarsini (C)

ICMR-National Institute for Research in Tuberculosis, Chetput, Chennai, India. Electronic address: padmapriyadarsinic@nirt.res.in.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH